Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia Morie A. Gertz, Rafael Fonseca, S. Vincent Rajkumar Oncologist 2000; 5:63-67 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine regarding lymphoma's and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Distinguish the features of monoclonal gammopathy of undetermined significance from those of Waldenström's macroglobulinemia. Recognize the established prognostic factors useful in predicting outcomes in Waldenström's macroglobulinemia. Understand the relative merits of alkylating agents, purine nucleoside analogs, and Rituximab in the treatment of Waldenström's macroglobulinemia. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Jul. 10, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Jul. 10, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.